{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:50:56Z","timestamp":1775170256251,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T00:00:00Z","timestamp":1440979200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.6061\/clinics\/2015(08)04","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T10:52:52Z","timestamp":1438944772000},"page":"550-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors \u2013 a single center experience"],"prefix":"10.1016","volume":"70","author":[{"given":"Beatriz Felicio","family":"Ribeiro","sequence":"first","affiliation":[]},{"given":"Eliana C M","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Dulcin\u00e9ia Martins","family":"de Albuquerque","sequence":"additional","affiliation":[]},{"given":"M\u00e1rcia T","family":"Delamain","sequence":"additional","affiliation":[]},{"given":"Gislaine","family":"Oliveira-Duarte","sequence":"additional","affiliation":[]},{"given":"Maria Helena","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Bruna","family":"Verg\u00edlio","sequence":"additional","affiliation":[]},{"given":"Rosana Antunes","family":"da Silveira","sequence":"additional","affiliation":[]},{"given":"Vagner","family":"Oliveira-Duarte","sequence":"additional","affiliation":[]},{"given":"Irene","family":"Lorand-Metze","sequence":"additional","affiliation":[]},{"given":"Carmino A","family":"De Souza","sequence":"additional","affiliation":[]},{"given":"Katia B B","family":"Pagnano","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"1","key":"10.6061\/clinics\/2015(08)04_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"10.6061\/clinics\/2015(08)04_bib2","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"8","key":"10.6061\/clinics\/2015(08)04_bib3","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.6061\/clinics\/2015(08)04_bib4","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"25","key":"10.6061\/clinics\/2015(08)04_bib5","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.6061\/clinics\/2015(08)04_bib6","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.6061\/clinics\/2015(08)04_bib7","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"35","key":"10.6061\/clinics\/2015(08)04_bib8","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.6061\/clinics\/2015(08)04_bib9","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"issue":"24","key":"10.6061\/clinics\/2015(08)04_bib10","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","article-title":"Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.6061\/clinics\/2015(08)04_bib11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5581\/1516-8484.20110056","article-title":"Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase \u2013 the importance of a major molecular response","volume":"33","author":"Machado","year":"2011","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"6","key":"10.6061\/clinics\/2015(08)04_bib12","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V82.6.1929.1929","article-title":"Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation","volume":"82","author":"Cross","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.6061\/clinics\/2015(08)04_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.6061\/clinics\/2015(08)04_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.6061\/clinics\/2015(08)04_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2006-07-035493","article-title":"Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure","volume":"109","author":"Quintas-Cardama","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.6061\/clinics\/2015(08)04_bib16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2010.110","article-title":"Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy","volume":"24","author":"Giles","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.6061\/clinics\/2015(08)04_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.6061\/clinics\/2015(08)04_bib18","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.6061\/clinics\/2015(08)04_bib19","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"issue":"35","key":"10.6061\/clinics\/2015(08)04_bib20","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.6061\/clinics\/2015(08)04_bib21","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.6061\/clinics\/2015(08)04_bib22","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.6061\/clinics\/2015(08)04_bib23","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1182\/blood-2010-06-291922","article-title":"Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy","volume":"116","author":"Ibrahim","year":"2010","journal-title":"Blood"},{"issue":"20","key":"10.6061\/clinics\/2015(08)04_bib24","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood-2009-05-221531","article-title":"The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up","volume":"114","author":"Garg","year":"2009","journal-title":"Blood"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222013461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222013461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/clinics.org.br\/uploads\/artigos\/clin-70-08\/cln-70-08-550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:01:49Z","timestamp":1761721309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222013461"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_abstract&pid=S1807-59322015000800550&lng=en&nrm=iso","label":"SCIELO"},{"URL":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4518767\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1807593222013461"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2015(08)04","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors \u2013 a single center experience","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2015(08)04","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}